Davis J M, Kane J M, Marder S R, Brauzer B, Gierl B, Schooler N, Casey D E, Hassan M
Illinois State Psychiatric Institute, Chicago.
J Clin Psychiatry. 1993 Mar;54 Suppl:24-30.
A review of the literature concerning the use of oral and depot antipsychotic medication has high-lighted some important considerations in the treatment of chronic schizophrenic patients. All patients not treated with any form of antipsychotic drug will relapse within 3 years. These relapses will be more clinically significant and will occur at greater frequency than in patients who receive medication on a regular basis. Careful consideration should be given to each patient when choosing between oral or depot medication and inpatient or outpatient therapy. In addition, the clinician should consider the dosage schedule of each medication and balance this against the probability of extrapyramidal side effects and noncompliance. One option for the prevention of relapse without an increase in adverse side effects is the administration of depot haloperidol. For all therapeutic options, medication should be given on a regular basis, since intermittent dosing strategies do not work, and psychosocial rehabilitation should be initiated.
一项关于口服和长效抗精神病药物使用的文献综述突出了慢性精神分裂症患者治疗中的一些重要考量因素。所有未接受任何形式抗精神病药物治疗的患者在3年内都会复发。与定期接受药物治疗的患者相比,这些复发在临床上更为显著,且发生频率更高。在选择口服或长效药物以及住院或门诊治疗时,应仔细考虑每位患者的情况。此外,临床医生应考虑每种药物的给药方案,并权衡其与锥体外系副作用和不依从性的可能性。预防复发且不增加不良副作用的一种选择是给予长效氟哌啶醇。对于所有治疗方案,药物都应定期给予,因为间歇给药策略无效,并且应启动心理社会康复。